Class Action Lawsuit Filed Against ADMA Biologics Amid Allegations of Securities Fraud
A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) over alleged securities fraud and misleading business practices. The firm Pomerantz LLP is representing investors who suffered losses following a short report by Culper Research, which led to significant declines in ADMA's stock price.
Tickers: $ADMA